Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH: Brexpiprazole maintenance in schizophrenia
NCT01397786Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2011
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Sep 2011; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01397786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01397786.